SANTA MONICA, Calif., April 23 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which recently announced it has decreased long-term debt by $1.75 million in 2009, said today it has eliminated another $817,000 of long-term debt.
"The remaining debt with YA Global Investments, formerly Cornell Capital Partners, has been assigned to an existing institutional investor. CBAI and YA Global Investments agreed on a one time common share settlement for liquidated damages in connection with assigning the outstanding principal and interest to the existing investor. With this assignment, CBAI has no further debt with YA Global Investments. Cord Blood America regards this as a key milestone on its path to being able to operate on its cash flow," said Matthew Schissler, Cord Blood America Founder and CEO. "We are happy to have worked with YA Global Investments and wish them future success."
"We said decreasing debt would be one of our significant items to focus on in 2009 and we are very pleased on how we are progressing," said Mr. Schissler. "Eliminating debt makes out financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 firstname.lastname@example.org
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved